李氏大藥廠(00950.HK)附屬獲PanOptica抗VEGF眼藥水在華等區域獨家權利
格隆匯7月2日丨李氏大藥廠(00950.HK)宣佈，於2020年6月25日，公司附屬兆科眼科與PanOptica, Inc.(一間專注眼科藥品的美國醫藥公司，為治療因血管異常或滲漏引致對視力構成威脅的眼部疾病而開發外用眼藥水)就於中國大陸、香港、澳門、南韓及東南亞其他國家開發、製造及商品化PAN-90806的獨家權利訂立一份具法律約束力的意向書。訂約雙方計劃在全球合作開發PAN-90806，該藥物乃用於治療濕性老年性黃斑部病變及其他潛在新生血管性眼部疾病(如糖尿病性視網膜病)(“授權安排”)。
在發達國家，濕性老年性黃斑部病變是引致失明的最常見成因，佔全球所有失明個案的8.7%。這種疾病會出現異常血管增生(又稱血管新生)及眼球后壁液體積聚，導致喪失視力。目前，絕大部分濕性老年性黃斑部病變的治療方式皆針對血管新生的因素－即血管內皮生長因子及透過玻璃體內注射控制病情。然而，玻璃體內注射可引致病人出現併發症及感到不適，手術期間患者所需的接送與照顧，亦對看護人增添額外負擔，導致低依順性、失去跟進治療機會及病情的不必要惡化。近期研發的治療方式嘗試透過減少玻璃體內注射控制病情的次數(由每月一次減少至數月一次)克服此問題。然而，玻璃體內注射手術仍是控制此慢性漸進性疾病的主要障礙。PAN研發的PAN-90806採取獨有的治療方式以眼藥水控制病情，可能成為治療濕性老年性黃斑部病變的突破。
PAN-90806是每日一次外用的小分子血管內皮生長因子受體2酪氨酸激酶抑制劑，可防止血管新生及血管滲漏。專門設計的專利配方使PAN-90806透過脈絡膜毛細血管循環到達眼球后壁併產生療效，同時降低其於眼球前壁的有效濃度，以避免潛在的脱靶不良反應。在美國進行的至少兩項臨牀試驗均有徵象顯示PAN-90806的療效，例如視力提高及視網膜厚度減少。目前正計劃在中國進行二期橋接臨牀試驗以確認及進一步探討該等結果。
公司認為，PAN-90806將會改變治療濕性老年性黃斑部病變的遊戲規則。多項臨牀試驗證明，抑制血管內皮生長因子可有效治療濕性老年性黃斑部病變。眼藥水配方可單獨或與其他玻璃體內注射療法組合使用，是對抗該衰竭性疾病並降低給藥頻率的一種非創傷、更方便且更易持續使用的替代療法。抑制血管內皮生長因子是療法的基礎，且改善該等衰竭性疾病患者的安全性、便利性、患者可及性以及最終臨牀結果的終生玻璃體內注射替代療法是一項迫切需求。
董事會確認，PAN與兆科眼科將根據意向書所述而進行的合作將具有高度協同性及互利性，乃由於此合作利用了各方的互補優勢、資源及專業知識。授權安排鬚受限於(其中包括)籤立具法律約束力的交易協議。PAN及兆科眼科擬於2020年第三季度前完成交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
